Antag Therapeutics is in focus this week after naming Philip Just Larsen, M.D., Ph.D., as Chief Executive Officer while its lead obesity and diabetes candidate advances toward mid-stage testing. The Danish biotech, which targets metabolic diseases, framed the developments as part of a broader shift into a more execution-focused clinical phase.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Larsen moves into the CEO role from his long-standing position as chairman, a post he has held since January 2018, providing continuity as he assumes operational leadership. He brings more than 20 years of R&D experience in metabolic disease and obesity at major firms including Bayer, Novo Nordisk, Eli Lilly, AstraZeneca, and Sanofi.
His prior work includes overseeing early research that contributed to dual incretin agonists such as tirzepatide and mazdutide, underlining deep domain expertise in advanced obesity pharmacology. Antag’s board leadership described him as central to the company’s scientific and strategic evolution, now tasked with driving clinical and partnering execution.
The CEO transition coincides with preparations to move AT7687, a first-in-class GIP receptor antagonist peptide, into a Phase 2a clinical trial expected to start in mid-2026. The company views this study as a key value inflection point for its strategy in obesity and diabetes, where competitive intensity and investor scrutiny are rising.
Antag plans to present new data from a completed first-in-human Phase 1 trial of AT7687 at the American Diabetes Association 2026 Scientific Sessions in New Orleans. These data are expected to provide further validation on safety, tolerability, and biomarker effects ahead of Phase 2a initiation, which will be closely watched by potential partners.
Built on decades of research by GLP-1 pioneer Jens Juul Holst, AT7687 is designed to selectively block the GIP receptor, a pathway associated with fat storage, insulin resistance, and broader metabolic dysfunction. Preclinical findings cited by the company show a favorable tolerability profile without dose titration and improvements across cardiovascular and body composition biomarkers.
Antag also emphasizes the peptide’s flexible formulation potential, supporting standalone use or co-formulations with other obesity drugs that could broaden future commercialization routes. Supported by an €80 million Series A round led by Versant Ventures with participation from Novo Holdings and others, the company says it has the capital and specialist leadership to advance AT7687 through mid-stage development.
From a financial and strategic perspective, the appointment of an R&D-focused CEO with a strong track record in incretin-based therapies may enhance trial design quality and partnering appeal. Overall, this week marked a pivotal transition for Antag Therapeutics as it shifts from platform building toward value-defining clinical execution for its lead obesity program.